Nigel W Crawford1,2,3, Kate Hodgson1, Mike Gold4, Jim Buttery2,5, Nicholas Wood6. 1. a Department of General Medicine , Royal Children's Hospital (RCH) , Melbourne , Australia. 2. b SAEFVIC, Murdoch Childrens Research Institute (MCRI) , Melbourne , Australia. 3. c Department of Paediatrics , The University of Melbourne , Melbourne , Australia. 4. d Discipline of Paediatrics, University of Adelaide , Adelaide , Australia. 5. e Monash Health & Monash University , Melbourne , Australia. 6. f Westmead Children's Hospital , Sydney , Australia.
Abstract
OBJECTIVE: To formalise a collaborative national Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN) following the expansion of the Australian Human Papillomavirus (HPV) immunisation program to boys in 2013. METHODS: AEFI-CAN linked state-based vaccine safety clinics and the Department of Health including the Therapeutic Goods Administration (TGA). Monthly teleconferences held to discuss HPV related cases. AEFI conditions of interest recorded in a centralised database. RESULTS: Between 1st January 2013 - 31st October 2014, 118 HPV AEFI were documented, 56% in males. The median age was 13 y (range 12-16 years). The majority of AEFI reports were after dose 1 (59%). 76 of 118 (64%) AEFI were seen in a vaccine safety clinic: 62% in Victoria, NSW (16%), South Australia (9%) and Western Australia (8%). Eight TeleHealth consultations were undertaken. AEFI were categorised as: rash 24% of reports (n = 28), urticaria/angioedema 23% (n = 27), anaphylaxis 3% (n = 4). Syncope was also reported (n = 12, 10%) and other neurological events (n = 22, 19%). CONCLUSIONS: We demonstrated the advantages of a national network, providing a collaborative approach to AEFI review and management. The vaccine safety network has applicability to any vaccination program, and has potential to collaborate more broadly with regional pharmacovigilance partners such as New Zealand.
OBJECTIVE: To formalise a collaborative national Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN) following the expansion of the Australian Human Papillomavirus (HPV) immunisation program to boys in 2013. METHODS: AEFI-CAN linked state-based vaccine safety clinics and the Department of Health including the Therapeutic Goods Administration (TGA). Monthly teleconferences held to discuss HPV related cases. AEFI conditions of interest recorded in a centralised database. RESULTS: Between 1st January 2013 - 31st October 2014, 118 HPV AEFI were documented, 56% in males. The median age was 13 y (range 12-16 years). The majority of AEFI reports were after dose 1 (59%). 76 of 118 (64%) AEFI were seen in a vaccine safety clinic: 62% in Victoria, NSW (16%), South Australia (9%) and Western Australia (8%). Eight TeleHealth consultations were undertaken. AEFI were categorised as: rash 24% of reports (n = 28), urticaria/angioedema 23% (n = 27), anaphylaxis 3% (n = 4). Syncope was also reported (n = 12, 10%) and other neurological events (n = 22, 19%). CONCLUSIONS: We demonstrated the advantages of a national network, providing a collaborative approach to AEFI review and management. The vaccine safety network has applicability to any vaccination program, and has potential to collaborate more broadly with regional pharmacovigilance partners such as New Zealand.
Authors: Julia Ml Brotherton; Michael R Batchelor; Michelle O Bradley; Scott A Brown; Simone M Duncombe; Dennis Meijer; Lauren E Tracey; Maureen Watson; Rosalind J Webby Journal: Commun Dis Intell Q Rep Date: 2015-06-30
Authors: Nigel W Crawford; Hazel Clothier; Kate Hodgson; Gowri Selvaraj; Mee Lee Easton; Jim P Buttery Journal: Expert Rev Vaccines Date: 2013-12-18 Impact factor: 5.217
Authors: Daryl R Cheng; Kirsten P Perrett; Sharon Choo; Margie Danchin; Jim P Buttery; Nigel W Crawford Journal: Vaccine Date: 2015-02-16 Impact factor: 3.641
Authors: F T Cutts; S Franceschi; S Goldie; X Castellsague; S de Sanjose; G Garnett; W J Edmunds; P Claeys; K L Goldenthal; D M Harper; L Markowitz Journal: Bull World Health Organ Date: 2007-09 Impact factor: 9.408
Authors: Hazel J Clothier; Katherine J Lee; Vijaya Sundararajan; Jim P Buttery; Nigel W Crawford Journal: Med J Aust Date: 2013-06-03 Impact factor: 7.738
Authors: Karina A Top; Robert T Chen; Ofer Levy; Al Ozonoff; Bruce Carleton; Nigel W Crawford; C Buddy Creech; Sonali Kochhar; Gregory A Poland; Kimberley Gutu; Clare L Cutland Journal: Clin Infect Dis Date: 2022-08-15 Impact factor: 20.999